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Summary: To study the existence of different mutations in acute intermittent porphyria, erythrocyte por-
phobilinogen deaminase activity and enzyme protein concentration were investigated in 125 porphyria gene
carriers from 31 families, and in 121 apparently healthy controls. Porphobilinogen deaminase concentration
^g/gHb) was quantified using a recently developed double-sandwich ELISA. The ratio of enzyme catalytic
activity to the concentration of enzyme protein was expressed s the porphobilinogen specific activity (nkat/g).
The controls had a mean porphobilinogen deaminase concentration of 160 ± 35 μg/gHb and a specific activity
of 762 ±127 nkat/g. Two different types of mutation causing acute intermittent porphyria were detected. The
majority (91%) of gene carriers, from 25 families, had a diminished porphobilinogen deaminase concentration
of 102 ± 18 μg/gHb, with a slightly lowered specific activity of 634 ±105 nkat/g. In 9% of the gene carriers,
representing six different families, an increase in porphobilinogen deaminase concentration to 269 ± 46
μg/gHb, and a highly significant reduction in specific activity to 234 ± 48 nkat/g, were found, which indicates
the presence of a different mutation.
Introduction have a reduced activity of porphobilinogen
Acute intennittent porphyria is a dominantly inher- deaminase1). Measurement of the erythrocyte activity
ited (1) inborn error of haem biosynthesis characte- of the enzyme has proved to be a valuable tool in the
rized by abdominal and neuropsychiatric Symptoms detection of latent carriers of the disease. However,
(2, 3). The gene carrier state is pften asymptomatic. there exists an overlap zone of enzyme activity, where
Certain drugs, hormones, steroids, infections and star- both acute intermittent porphyria gene carriers and
vation may precipitate acute attacks of the disease. non-carriers are found (4—9).
Hepatic 5^-aminolaevulinic acid synthase activity is u u i j
. j , , . , . ..
 r c . The porphobilinogen deaminase gene has been clonedinduced and an mcreased unnary excretion of 5-ami-
 /4 ΛΧ f , 7 Λ Γ' *. /^ <~>\
,. - .. j , , ·ι · rr * 0°) and shown to code for two enzymes (11, 12).
nolaevulinic acid and porphobilinogen occur. Meter- X
 r /a, „„ΛΛΛ\ - r Λ ^ · ^ - *u
• - — *·Λ* * One form (Μτ 42000) is found exclusively m erytho-
ozygotes for the acute intermittent porphyria gene . j «. Λ Λ · /Λ ^>ΙΛΛΛ\ ·
^ r r poietic tissue, and an extended Version (Afr 44000) is
present in non-erythropoietic cells. The cloned gene
0
 pSrSiHnogen deaminase (syn: uroporphyrinogen-I-syn- has ^en used for restriction fragment length poly-
thetase, hydroxymethylbilane synthetase) EC 4.3.1.8 morphism studies (13,14), and in informative families
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this approach has been of diagnostic value. Porpho-
bilinogen deaminase has been purified and mono-
specific polyclonal anitbodies against the enzyme have
been produced in rabbits (15-19). Different classes
of enzyme defect have been identified from the
amount of immunologically cross-reacting enzyme
material (CRIM) in erythrocyte lysates of acute in-
termittent porphyria heterozygotes. Four classes of
mutation were identified with the use of rocket im-
munoelectrophoresis (15-17), two CRIM-negative
and two CRIM-positive. The majority of CRIM-
negative families, designated type l, exhibited half-
normal porphobilinogen deaminase activity, which
was accounted for by a reduction of porphobilinogen
deaminase protein. Some families had a normal eryth-
rocyte enzyme activity (20) and were designated
CRIM-negative type 2. Other families had CRIM-
positive mutations. One type had moderately elevated
concentrations of porphobilinogen deaminase protein
in erythrocyte lysate and was designated CRIM-po-
sitive type l. The other CRIM-positive mutation, type
2, had markedly more enzyme protein. In the present
study a Swedish collective of acute intermittent por-
phyria heterozygotes and normal controls was inves-
tigated for erythrocyte porphobilinogen deaminase
activity, porphobilinogen deaminase protein concen-
tration measured by ELISA (21) and porphobilinogen
deaminase specific activity, i.e. enzyme activity re-
lated to the concentration of enzyme protein.
Materials, Methods and Human Subjects
Materials
Microtitre plates and an Immunowash 8 were obtained from
Nunc (Roskilde, Denmark). ELISA absorbances were read in
a MR 700 Microplate reader, Dynatech Laboratories (Guera-
sey, Great Britain). Evacuated heparinized test tubes were pur-
chased from Becton-Dickinson (Plymouth, Great Britain).
Porphobilinogen deaminase activity
The activity of porphobilinogen deaminase in erythrocyte lysate
was measured according to the method of Magnussen et al.
(22). The enzyme activity was expressed in two ways: picokatal
per gram haemoglobin (pkat/g Hb) and nanokatal per litre red
blood cells (nkat/1). The latter method of calculation was em-
ployed in the original publication, and it is used again here to
facilitate comparison with earlier reports and earlier investi-
gations in our laboratory.
The ELISA
A monospecific polyclonal antiserum was raised in rabbits
against the erythropoietic form of porphobilinogen deaminase,
purified from human red blood cells (23). For immunological
quantification of porphobilinogen deaminase enzyme protein
in human erythrocyte lysate, a double-sandwich enzyme-linked
immunosorbent assay (ELISA) was developed (21). The IgG
fraction used was shown to be monospecific by immunoblot-
ting, rocket inununoelectrophoresis and immunotitratiön. A
measuring ränge from 4 ng to 50 pg was demonstrated. Intra-
and inter-assay coefficients of Variation were 6% and 7% re ·^
spectively.
Lysis of the erythrocytes was achieved by freezing at — 20 °C
and thawing. Prior to analysis, 25 of the lysate was diluted
by adding 100 ml of 50 mmol/1 Tris-HCl pH 7.5, 0.15 mol/1
NaCl. One hundred of the l: 4000 dilution was added to
each of the microtitre plate wells. Duplicate samples were used.
Erythrocyte lysate from a patient with a high concentration of
porphobilinogen deaminase, äs determined by titration against
the purified enzyme, was used äs an internal Standard and
included in each assay. Haemoglobin concentration was mea-
sured in the diluted erythrpcyte lysate samples in the MR 700
Microplate reader äs the absorbance at 410 nm. Assay results
were expressed äs microgram porphobilinogen deaminase en·^
zyme protein per gram haemoglobin ( ^/g Hb).
Specific activity
The porphobilinogen deaminase specific activity was deter=
mined in erythrocyte lysates from controls and acute intermit^
tent porphyria by dividing the porphobilinogen deaminase ac-
tivity (pkat/g Hb) by the porphobilinogen deaminase protein
concentration fag/g Hb) äs measured by ELISA. The specific
activity was expressed äs nanokatal per gram porphobilinogen
deaminase enzyme protein (nkat/g).
Human subjects
Carriers of the acute intermittent porphyria gene, 125 individ-
uals from 31 different families, were investigated. According to
geneajogical data, 68 of the carriers were descended from the
large family frorn nprthern Sweden first described by Waiden·?
ström (l, 24). The diagnosis of acute intermittent porphyria
was documented by a careful investigation of biochemical find·^
ings, family history of acute intermittent porphyria and clinical
Symptoms. Eighty nine of the 125 acute intermittent porphyria
gene carriers were investigated for 5-aminolaevulinate and por-
phobilinogen in the urine. Excess excretion was found in 82 of
them and in seven a normal amount of S-^aminolaevulinate and
porphobilinogen was found. The other 36 acute intermittent
porphyria gene carriers were diagnosed only by porphobilino-
gen deaminase activity. There was no statistically significant
difference in porphobilinogen deaminase activity between these
groups (unpaired t-test, p < 0.001). As controls, 121 äpparently
healthy individuals of raatching age and sex were used.
Blood samples
Heparinized blood was collected by venous puncture and sent
by post to the laboratory. After centrifugation at 2000 g for 10
minutes at room temperature, the plasma was carefully re-
moved. The erythrocytes were stored at ^-20 °C up to six
moiiths before assay. Storage within this period of tirae did not
affect the assay results.
Results
Erythrocyte porphobilinogen deaminase ac-
tivity
Figures l a und b show the erythroeyte porphobili-
nogen deaminase activity in contrqf persons and in
acute intermittent porphyria heterozygotes, expressed
äs pkat/g Hb and nkat/1. The erythrocyte porphobi-
linogen deaminase activity was 120 ± 26 pkat/g Hb
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Fig. 1 Erythrocyte porphobilinogen deaminase enzyme activ-
ity in acute intermittent porphyria heterozygotes and in
controls, enzyme activity expressed s pkat/g Hb (a)
and nkat/1 (b). One point represents one individual.
(36 ± 8 nkat/1) for the controls and 65 ± 16 pkat/g
Hb (20 ± 5 nkat/1) for the acute intermittent porphy-
ria gene carriers. A considerable overlap in activity
between controls and patients is noted, in agreement
with previous reports (4—9). At the time of the in-
vestigation one of the acute intermittent porphyria
heterozygotes had a metastatic carcinoma of the pros-
tate and severe anaemia with a haemoglobin concen-
tration of 70 g/l. This patient exhibited a substantially
increased porphobilinogen deaminase activity of 189
pkat/g Hb (58 nkat/1), (tab. 1), which is more than
+ 3 SD outside the mean for the remaining patients
in the group. Three years earlier, when the patient
had a normal haemoglobin concentration, his eryth-
rocyte porphobilinogen deaminase activity was 20
nkat/1.
Erythrocyte porphobilinogen deaminase en-
zyme protein concentration
Figure 2 shows the porphobilinogen deaminase en-
zyme protein concentration in controls and acute in-
termittent porphyria heterozygotes. The controls had
a porphobilinogen deaminase concentration of
160 + 35 μg/gHb. The acute intermittent porphyria
heterozygotes feil into two distinct groups. More than
90% of the patients (n = 113) from 25 different fami-
lies, exhibited a lower concentration (102 ± 18 μg/g
Hb), compared with the controls, which indicates a
CRIM-negative mutation. However, 12 acute inter-
mittent porphyria heterozygotes (9%) from six dif-
ferent families, had a markedly raised concentration
of277 ± 52 μg/g Hb, which signifies a CRIM-positive
mutation.
Tab. 1. Erythrocyte porphobilinogen deaminase (PBGD) activity, enzyme protein concentration and specific activity in 121
controls and 125 acute intermittent porphyria heterozygotes.
Acute intermittent
porphyria
n = 195
Acute intermittent Acute intermittent
porphyria porphyria
CRIM negative, n = 113 CRIM positive, n = lla)
Mean S.D. Range Mean S.D. Range Mean S.D. Range Mean S.D. Range
PBGD activity
(pkat/g Hb)
PBGD activity
( kat/1)
PBGD
concentration
^g/g Hb)
PBGD specific
activity
(nkat/g)
120
36
160
762
26
8
35
127
63- 225
19 ·^ 70
102- 268
522-1189
65
20
119
600
16
5
57
149
38-189
11- 58
63-363
170-950
64
20
102
634
11
3
18
105
38-114
11- 30
63-148
430-950
61
19
269
234
6
2
46
48
52- 69
16- 24
210-344
171-320
a) One CRIM-positive patient was excluded (see Discussion), with a porphobilinogen deaminase activity of 189 pkat/gHb (58
nkat/1), a porphobilinogen deaminase concentration of 363.^g/g Hb and a porphobilinogen deaminase specific activity of 520
nkat/g.
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Fig. 2. Concentration of immunologically detectable porpho-
bilinogeix deaminase protein in erythrocyte lysates in
acute intermittent porphyria heterozygotes and in con-
trols, measured by ELISA.
Fig. 3. Erythrocyte porphobilinogen deaminase specific activity
in controls and in CRlM-negative and CRIM-positive
acute intennittent porphyria heterozygotes. Individuais
belonging to the same CRlM-negative family from
northern Sweden are plotted separately.
CRIM = immunologically cross-reacting enzyme ma-
terial
Erythrocyte porphobilinogen deaminase spe-
cific activity
The erythrocyte porphobilinogen deaminase specific
activity for the controls was 762 ±127 nkat/g. A
significantly lower figure of 634 ±105 nkat/g (un-
paired t-test5 p < 0.001) was obtained for the CRIM-
negative acute intermittent porphyria heterozygotes.
Sixty eight of the 113 acute intermittent porphyria
heterozygotes were descended from one large Swedish
family. They had the same distribution of values for
porphobilinogen deaminase specific activity s the
other individuals in the CRIM-negative group (fig.
3). The CRIM-positive gene carriers, with raised por-
phobilinogen deaminase concentration, exhibited a
highly significant reduction in specific activity to 234
± 48 nkat/g (n = 11) (tab. 1). One patient with raised
specific activity, a proband in a CRIM-positive family
(fig. 4, marked by arrow), was excluded (see
Discussion). The inheritance of a CRIM-positive
mutation is demonstrated in figure 4.
Discussion
An ELISA method for use in porphyria routine diag-
nostic work was developed previously (21) for quan-
tit tion of porphobilinogen deaminase enzyme pro-
tein concentration in erythrocyte lysates. In the pres-
ent work it was applied in the study of a pop lation
of Swedish acute intermittent porphyria gene carriers.
. Two classes of mutations were revealed, one CRIM-
negative with a low concentration of porphobilinogen
deaminase enzyme protein and one CRIM-positive
with a high porphobilinogen deaminase concentra-
tion, compared with controls. The CRIM-positive
carriers exhibited a highly significant reduction in
porphobilinogen deaminase specific activity, which
indicates that immunoreactive non-cat lytic enzyme
protein encoded by the mutant allele was detected by
the ELISA. The CRIM-positive carriers also had a
considerable increase of catalytically inactive protein
and are probably of a type similar to the CRIM-
positive type 2 class, previously described (17), which
may be caused by a mutation in the structur l gene.
However, the CRIM-negative acute intennittent por-
phyria heterozygotes also had a significantly lowered
porphobilinogen deaminase specific activity, although
not of the same magnitude s the CRIM-positive
group. In a pure regulatory gene defect the mutant
allele is not considered to producc an enzyme wilh
diminished activity. The CRIM-negative mutation(s)
may thus represent changes in the DNA, leading to
altered enzyme stability, mRNA transcription or
processing.
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Fig. 4. A CRIM-positive acute intermittent porphyria family. Figures under Symbols denote values obtained for porphobilinogen
deaminase activity expressed s pkat/g Hb (upper), porphobilinogen deaminase concentration expressed s μg/g Hb
(middle) and, in bold type, the porphobilinogen deaminase specific activity expressed s nkat/g (lower).
ID deceased acute intermittent phorphyria heterozygote
ο, α unaffected
o acute intermittent porphyria heterozygote with clinically manifest disease
® not investigated
4D, D asymptpmatic acute intermittent porphyria heterozygote
α proband with anaemia and metastatic cancer of the prostate
In the CRIM-positive family presented in figure 4,
the inheritance of the Imitation was clearly demon-
strated, s all gene carriers showed an increased por-
phobilinogen deaminase concentration. All carriers
also showed a decreased porphobilinogen deaminase
specific activity, except the proband with anaemia and
metastatic cancer of the prostate, who feil more than
+ 3 SD outside the group in this respect. He h d a
porphobilinogen deaminase concentration of the same
magnitude s the other gene carriers in the family but
considerably raised enzyme activity, which explairis
the increase in porphobilinogen deaminase specific
activity to 520 nkat/g. Statistically he was not repre-
sentative f the CRIM-positive^ group. It has been
reported that the porphobilinogen deaminase enzyme
activity in red blood cells is also subject to regulation
by factprs other than the major gene on chromosome
11 (25). It has further been shown that porphobili-
nogen deaminase activity may be increased in hae-
molytic disorders, in liver cirrhosis and other liver
affections and in malignancies (26—28).
By measuring porphobilinogen deaminase protein
concentration in addition to porphobilinogen deami-
nase activity, different mutations of acute intermittent
porphyria can be distinguished. The Information
gained may be of diagnostic value, since in CRIM-
positive families the raised porphobilinogen deami-
nase enzyme protein concentration and the decreased
porphobilinogen deaminase specific activity distin-
guish between carriers and non-carriers of the gene
defect. In CRIM-negative mutations, the porphobi-
linogen deaminase enzyme protein quantification
yields additional Information on the erythrocyte en-
zyme. The diagnostic potential of this Information
will be further evaluated. However, the ELISA
method now available is less time-consuming than the
traditional enzyme activity assay. It therefore offers
a new means of rapidly investigating a large number
of samples from populations at risk for the disease.
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